- Conditions
- Urea Cycle Disorders, Carbamoyl-Phosphate Synthase I Deficiency
- Interventions
- LNP.UCD.ABE
- Biological
- Lead sponsor
- Rebecca Ahrens-Nicklas
- Other
- Eligibility
- 24 Hours to 5 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Virus Diseases
- Interventions
- 1 µg CoV2 SAM (LNP)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD
- Interventions
- ARCT-810
- Biological
- Lead sponsor
- Arcturus Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chevy Chase, Maryland
- Conditions
- COVID-19
- Interventions
- AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9%
- Drug · Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,270 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more
- Conditions
- Influenza
- Interventions
- Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Solid Tumor
- Interventions
- mRNA-LNP
- Genetic
- Lead sponsor
- IntraAb, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Richmond, California
- Conditions
- COVID-19, COVID-19 Immunisation
- Interventions
- mRNA-1273, mRNA-1273.351
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • Cincinnati, Ohio • Nashville, Tennessee + 1 more
- Conditions
- COVID-19
- Interventions
- ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
- Conditions
- Advanced Solid Tumor
- Interventions
- STX-003, KEYTRUDA®
- Biological
- Lead sponsor
- Strand Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Nashville, Tennessee
- Conditions
- Influenza
- Interventions
- cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Moderna COVID-19 Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 1,923 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more
- Conditions
- Influenza
- Interventions
- DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 629 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 21
- States / cities
- Anaheim, California • Walnut Creek, California • Hialeah, Florida + 16 more
- Conditions
- COVID-19
- Interventions
- Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 867 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
- Conditions
- Avian Influenza
- Interventions
- H5 AC-Anhui RNA Vaccine, H5 Astrakhan RNA Vaccine, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Nashville, Tennessee • Houston, Texas
- Conditions
- Advanced Solid Tumor
- Interventions
- STX-001, Keytruda®
- Biological
- Lead sponsor
- Strand Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Cleveland, Ohio + 3 more
- Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Interventions
- SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration
- Biological · Procedure · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- COVID-19, COVID-19 Immunisation
- Interventions
- mRNA-1273
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Decatur, Georgia • Bethesda, Maryland • Seattle, Washington
- Conditions
- Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Hepatocellular Cancer, Liver Cancer, Liver, Cancer Of, Non-Resectable
- Interventions
- OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two, Checkpoint Inhibitor, Immune
- Drug
- Lead sponsor
- Omega Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • Gainesville, Florida • Chicago, Illinois + 3 more
- Conditions
- Ornithine Transcarbamylase Deficiency
- Interventions
- ARCT-810, Placebo
- Biological · Other
- Lead sponsor
- Arcturus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- Gainesville, Florida • Minneapolis, Minnesota • New York, New York + 5 more
- Conditions
- Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection
- Interventions
- RSV/hMPV mRNA LNP 1, RSV/hMPV mRNA LNP 2, RSV mRNA LNP 1, hMPV mRNA LNP 1
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 558 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Gardena, California • Hallandale, Florida • Meridian, Idaho + 6 more